Amy Emerson is the Chief Executive Officer at the MAPS Public Benefit Corporation (MAPS PBC), a fully owned subsidiary of the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS).
Working for almost two decades to make MDMA a legal, FDA-approved medicine, Amy began as a pro bono consultant for MAPS in 2003, helping to create MAPS’ clinical department and managing the MDMA Clinical Development Program.
Her painstaking time and efforts have played a key role in seeing MDMA-assisted psychotherapy as a treatment for post-traumatic stress disorder (PTSD) through clinical trials, driving it ever-closer to being a legal, accessible therapeutic treatment in the US and abroad.
Read more
Michael Pollan looks at the legalization of some psychedelics and asks how should we do drugs now?
Read more
Check this out— For those looking to understand where, and how psychedelic laws are changing, Psychedelic Invest has created an in depth resource to track past and upcoming changes.
Read more
Will the federal government finally embrace the psychedelic revolution?
Read more
The first companies developing medical treatments from psychedelic drugs like LSD, ketamine and the active ingredient in magic mushrooms are gearing up to list on Canadian stock exchanges.
Read more
As cities decriminalize psychedelic fungi, advocates work to legalize statewide. Here’s an update.
Read more
Here is a handy guide explaining the legality around psychedelics. Note that most are still illegal in the US, except under certain conditions. And decriminalized does not mean legal!
Read more
This article looks at the benefits and risks of psychedelics, and the legal issues to be considered.
Read more
Michael Pollan takes a look at the pros and cons of legalizing psychedelic mushrooms, and the potential benefits and risks of taking them.
Read more